Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919774 · ClinicalTrials.gov registry record · Phase 1
Pomaglumetad Effects on Glutamate Biomarkers
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT02919774 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 95 participants.
The verdict
NCT02919774, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).
Interventions
- DRUG placebo
- DRUG POMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02919774
The ClinicalTrials.gov registry entry for NCT02919774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02919774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02919774 about?
NCT02919774 is a clinical study titled "Pomaglumetad Effects on Glutamate Biomarkers". The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).
What is the current status of trial NCT02919774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2016-10. Estimated completion is 2018-05-25.
What interventions are being tested in trial NCT02919774?
The interventions under investigation include: placebo (DRUG), POMA (DRUG).
Who is sponsoring clinical trial NCT02919774?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.